Schizophrenia Market Report 2026

Schizophrenia Market Overview

• Schizophrenia market size has reached to $6.06 billion in 2025 • Expected to grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Demand For Anxiety Treatment Fuels Schizophrenia Market • Market Trend: Technological advancements in the schizophrenia market to enhance treatment efficacy and patient adherence • North America was the largest region in 2025.

What Is Covered Under Schizophrenia Market?

Schizophrenia is a long-term and severe mental illness that profoundly impacts a person's cognitive processes, emotional expression, behavior, and perception of reality, with symptoms encompassing delusions, hallucinations, disordered speech, and peculiar movements. A comprehensive approach to the management of schizophrenia involves the application of pharmaceutical interventions, rehabilitation programs, and supportive services. The main types of schizophrenia are catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. Catatonic Schizophrenia refers to a subtype of schizophrenia characterized by severe motor disturbances, including catatonia, immobility, and unusual postures or movements, and antipsychotic medications and supportive therapies are used to manage psychotic symptoms and address catatonic motor behavior. The treatment includes first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs administered by oral and injectable routes.

What Is The Schizophrenia Market Growth Forecast?

The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to pipeline of novel antipsychotic molecules, growth in long-acting injectable formulations, rising government mental health initiatives, increasing access to treatment in emerging markets, integration of digital monitoring and adherence tools. Major trends in the forecast period include increasing use of long-acting injectable antipsychotics, shift toward second- and third-generation antipsychotic drugs, growing focus on early diagnosis and intervention programs, expansion of community-based and outpatient treatment models, rising adoption of combination therapy and adjunct treatments.

Global Schizophrenia Market Segmentation

1) By Type: Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, Other Types 2) By Treatment: First-Generation Antipsychotics, Second-Generation Antipsychotics, Third-Generation Antipsychotics, Psychotherapies, Other Treatments 3) By Route of Administration: Oral, Injectables Subsegments: 1) By Catatonic Schizophrenia: Waxy Flexibility, Stupor, Agitation, Catatonic Excitement 2) By Paranoid Schizophrenia: Delusions Of Persecution, Auditory Hallucinations, Paranoid Ideation 3) By Undifferentiated Schizophrenia: Symptoms Not Specific To Other Types, Mixed Symptoms Of Schizophrenia 4) By Hebephrenic Schizophrenia (Disorganized Schizophrenia): Disorganized Behavior, Disorganized Speech, Emotional Flatness 5) By Residual Schizophrenia: History Of Schizophrenia With Low-Level Symptoms, Social Withdrawal, Mild Hallucinations Or Delusions 6) By Other Types: Schizoaffective Disorder, Brief Psychotic Disorder, Delusional Disorder

What Is The Driver Of The Schizophrenia Market?

The rising demand for anxiety treatment is expected to propel the growth of the schizophrenia market going forward. Anxiety treatment refers to the various therapeutic approaches and interventions aimed at helping individuals who experience excessive and debilitating anxiety symptoms manage and alleviate their anxiety. Anxiety treatment can be helpful for individuals with schizophrenia in several ways, as it addresses comorbid anxiety symptoms that can often co-occur with schizophrenia. And it can also help reduce the intensity of psychotic symptoms such as hallucinations and delusions. For instance, in May 2024, according to a report by American Psychiatric Association, a US-based professional organization of psychologists, in 2024, 43% of adults reported feeling more anxious compared to 37% in 2023 and 32% in 2022, indicating a consistent increase in anxiety levels. Therefore, the rising demand for anxiety treatment is driving the growth of the schizophrenia industry.

Key Players In The Global Schizophrenia Market

Major companies operating in the schizophrenia market are Pfizer Inc, Johnson And Johnson Services Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Otsuka Holdings Co Ltd, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Sumitomo Dainippon Pharma Co Ltd, Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck AS, Neurocrine Biosciences Inc, Torrent Pharmaceutical Ltd, Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc, Intra Cellular Therapies Inc, Axsome Therapeutics Inc, Karuna Therapeutics Inc, Minerva Neurosciences Inc

Global Schizophrenia Market Trends and Insights

Major companies operating in the schizophrenia market are focusing on technological advancements, such as atypical oral antipsychotics with improved safety and efficacy profiles, to meet the rising demand driven by the need for better symptom control, expanded treatment options for adolescents, and improved tolerability. For instance, in March 2025, Otsuka Pharmaceutical Europe Ltd., a Japan-based healthcare company, in collaboration with H. Lundbeck A/S, a Denmark-based biopharmaceutical company, launched Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. Rxulti is an atypical oral antipsychotic taken once daily, which modulates serotonin and dopamine systems by acting as a partial agonist at serotonergic 5-HT1A and dopaminergic D2 receptors, along with antagonist activity at serotonergic 5-HT2A and noradrenergic α1B/2C receptors. This diverse receptor profile offers a balanced approach in controlling both positive and negative symptoms with a favorable safety profile, improving treatment adherence and patient outcomes compared to traditional antipsychotics. The European Commission’s approval was based on a rigorous 6-week randomized clinical trial demonstrating significant symptom reduction and good tolerability in adolescent patients.

What Are Latest Mergers And Acquisitions In The Schizophrenia Market?

In March 2023, Royalty Pharma PLC, a US-based buyer of biopharmaceutical royalties, acquired the royalty rights for KarXT schizophrenia treatment from Karuna Therapeutics Inc. for $500 million. With this acquisition, Royalty gives PureTech a 3% royalty on Karuna's annual sales of up to $2 billion. This acquisition also offers PureTech extra funds to advance its internal pipeline, including ongoing clinical programs, toward potential commercialization. KarXT is an oral investigational drug designed to treat schizophrenia and other neurological disorders, focusing on M1/M4-preferred muscarinic agonists. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing drugs for treating psychiatric disorders and schizophrenia.

Regional Outlook

North America was the largest region in the schizophrenia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Schizophrenia Market?

The schizophrenia market consists of revenues earned by entities by providing cognitive behavioral therapy, electroconvulsive therapy, and group counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizophrenia market also includes sales of risperdal, invega, zyprexa, geodon and seroquel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Schizophrenia Market Report 2026?

The schizophrenia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the schizophrenia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.